摘要
目的:观察何种剂量的米非司酮在治疗围绝经期子宫肌瘤中能达到治疗子宫肌瘤的同时成功诱导绝经的最佳效果。方法:收集围绝经期子宫肌瘤患者128例随机分为3组,给予不同剂量米非司酮治疗,服药3个月后复测患者子宫及肌瘤大小与治疗前进行比较,同时随访6个月观察诱导绝经情况。结果:不同剂量的3组患者,在治疗3个月后子宫肌瘤均有缩小,且差异具有统计学意义(P<0.05),但组间差异均无统计学意义(P>0.05)。随访各组中均有成功诱导闭经病例,其中以米非司酮12.5 mg/d组疗效明显,3组差异具有统计学意义(P<0.05)。结论:米非司酮是保守治疗围绝经期子宫肌瘤患者的有效药物,临床治疗推荐12.5 mg/d方案进行治疗。
Objective：To identify the indentified and proper doses of mifepristone not only to treat uterine flesh tumour but to induce successfully menopause during the treatment of perimenopausal uterine leiomyoma. Methods：128 cases of patients with perimenopausal uterine leiomyoma were randomly divided into three groups,who were given different doses of mifepristone. 3 months later,The sizes of patients＇ uterus and myoma were measured again,compared each other. At the same time,induced menopausal status were observed through 6 months＇ patients follow-up. Results：The uterine flesh tumours were averagely reduced in three groups of patients prescribed the different doses after three months ＇ treatment. and there was significant statistically difference（P〈0. 05）;while there was no any statistical difference between each group（P〉0. 05）. There were menopause cases induced in each group during the 6 months＇ follow-up,especially the patients treated by mifepristone 12. 5 mg/d. There was some statistically significant difference（P〈0. 05）in three groups. Conclusion：Mifepristone is the effective medicine to carry out the conservative treatment for perimenopausal uterine leiomyoma. Mifepristone 12. 5 mg/d is recommended in the clinical practice.
出处
《山西职工医学院学报》
CAS
2014年第4期3-5,共3页
Journal of Shanxi Medical College for Continuing Education
关键词
围绝经期
子宫肌瘤
米非司酮
诱导绝经
perimenopausal
uterine flesh tumour
mifepristone
menopause induced
